AtaiBeckley (ATAI) Long-Term Deferred Tax (2020 - 2025)
AtaiBeckley's (ATAI) quarterly Long-Term Deferred Tax came in at $165.4 million in Q4 2025, up 992.24% year-on-year from $15.1 million in Q4 2024, and up 992.24% quarter-over-quarter from $15.1 million in Q4 2024.
AtaiBeckley (ATAI) Long-Term Deferred Tax (2020 - 2025) Analysis & Trends
AtaiBeckley's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $165.4 million for Q4 2025.
- On a quarterly basis, Long-Term Deferred Tax rose 992.24% year-over-year to $165.4 million in Q4 2025; TTM through Dec 2025 was $165.4 million, a 992.24% increase from a year earlier, with the FY2025 full-year figure at $165.4 million, up 992.24% from the prior year.
- Long-Term Deferred Tax rose to $165.4 million in Q4 2025 per ATAI's latest filing, from $15.1 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $8.6 million in Q4 2021 to a low of $6.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 165.44 Mn |
| Dec 31, 2024 | 15.15 Mn |
| Dec 31, 2021 | 8.62 Mn |
| Dec 31, 2020 | 5.96 Mn |